Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases across the world, but there is still no specific treatment for NAFLD. Glucogon-like peptide 1 receptor agonist (GLP-1Ra) is a novel drug for the treatment of type 2 diabetes, based on incretin hormone target. Animal and clinical studies have demonstrated that GLP-1Ra can effectively reduce fat deposit in liver and attenuate hepatic steatosis. Therefore, GLP- 1Ra is a promising therapeutic approach against NAFLD. In this review, we provided an overview of the clinical and basic research evidences and mechanisms in relieving NAFLD.

Key words: glucagon-like peptide 1, incretins, fatty liver, review, glucogon-like peptide 1 receptor agonist, non-alcoholic fatty liver